Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Meanwhile, the company is shifting its weight-loss strategy toward FDA-approved branded GLP-1 therapies through its partnership with Novo Nordisk, expanding access to Wegovy and discontinuing compounded GLP-1 alternatives
The company had expected to make more than $700 million this year on weight-loss services, a target that could be difficult to reach without Wegovy sales
/assets/images/provider/photos/2767206.jpeg)
Research use only
USD 39.95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others Subjects Change history 28 May 2025 A Correction to this paper has been published: References Drucker, D
GLP-1Rs exhibit broad tissue distribution, spanning the pancreas, gastrointestinal tract, cardiovascular system, and central nervous system, allowing GLP-1 RAs to impact multiple organ systems 2,3
These restrictions help reduce the risk that compounders will prepare these unapproved drug products for patients whose medical needs could be met by an approved product
US$ 24.40
US$ 22.43
US$ 28.17
US$ 28.98
US$ 20.34
US$ 28.79
